Literature DB >> 1849315

A comprehensive immunological analysis in chronic fatigue syndrome.

S Gupta1, B Vayuvegula.   

Abstract

A detailed analysis of cell-mediated and antibody-mediated immunity was performed in 20 CDC-defined patients with chronic fatigue syndrome (CFS) and 20 age- and sex-matched healthy controls. CD3+, CD4+, CD8+, and CD20+ lymphocytes were comparable in two groups. Natural killer cells as defined by CD16, CD56 and CD57 antigens were significantly reduced in CFS. A significant increase in the proportions of CD4+ ICAM 1+ T cells was observed in CFS. Monocytes from CFS displayed increased density (as determined by mean fluorescence channel numbers) of intercellular adhesion molecule 1 (ICAM-1) and lymphocyte function associated antigen 1 (LFA-1), but showed decreased enhancing response to recombinant interferon-gamma in vitro. The lymphocyte DNA synthesis in response to phytohaemoglobulin (PHA), Concanavalin A (Con A) and pokeweed mitogen (PWM) was normal but the response to soluble antigens was significantly reduced. Serum IgM, IgG, IgA, and IgG subclasses were normal. In vivo specific antibody response to pneumococcus vaccine was depressed in CFS. Forty percent of patients showed titres of anti-human herpes virus 6 (anti-HHV-6) antibody higher than that in the controls (greater than or equal to 1/80). These data suggest immunological dysfunction in patients with chronic fatigue syndrome. The significance of these observations is discussed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849315     DOI: 10.1111/j.1365-3083.1991.tb01777.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

1.  Immunological response in chronic fatigue syndrome following a graded exercise test to exhaustion.

Authors:  J J LaManca; S A Sisto; X D Zhou; J E Ottenweller; S Cook; A Peckerman; Q Zhang; T N Denny; W C Gause; B H Natelson
Journal:  J Clin Immunol       Date:  1999-03       Impact factor: 8.317

Review 2.  Chronic fatigue syndrome: probable pathogenesis and possible treatments.

Authors:  Birgitta Evengård; Nancy Klimas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Evidence for the presence of immune dysfunction in chronic fatigue syndrome.

Authors:  Benjamin H Natelson; Mohammad H Haghighi; Nicholas M Ponzio
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

4.  Immune modulation with a staphylococcal preparation in fibromyalgia/chronic fatigue syndrome: relation between antibody levels and clinical improvement.

Authors:  O Zachrisson; P Colque-Navarro; C G Gottfries; B Regland; R Möllby
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-20       Impact factor: 3.267

Review 5.  The chronic fatigue syndrome.

Authors:  D G James; M G Brook; B A Bannister
Journal:  Postgrad Med J       Date:  1992-08       Impact factor: 2.401

6.  Double-blind, randomized study of the effects of influenza vaccination on the specific antibody response and clinical course of patients with chronic fatigue syndrome.

Authors:  K M Sleigh; D G Danforth; R T Hall; J A Fleming; H G Stiver
Journal:  Can J Infect Dis       Date:  2000-09

7.  Chronic Fatigue Syndrome: Do herbs or homeopathy help?

Authors:  E Leyton; H Pross
Journal:  Can Fam Physician       Date:  1992-09       Impact factor: 3.275

8.  Lymphocyte subset differences in patients with chronic fatigue syndrome, multiple sclerosis and major depression.

Authors:  M J Robertson; R S Schacterle; G A Mackin; S N Wilson; K L Bloomingdale; J Ritz; A L Komaroff
Journal:  Clin Exp Immunol       Date:  2005-08       Impact factor: 4.330

9.  The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome.

Authors:  D M See; P Cimoch; S Chou; J Chang; J Tilles
Journal:  Integr Physiol Behav Sci       Date:  1998 Jul-Sep

10.  Lymphocyte phenotype and function in the chronic fatigue syndrome.

Authors:  S E Straus; S Fritz; J K Dale; B Gould; W Strober
Journal:  J Clin Immunol       Date:  1993-01       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.